The development of a novel therapy using glycyrrhitinic acid for overactive bladder caused by lower urinary tract obstruction.

The development of a novel therapy using glycyrrhitinic acid for overactive bladder caused by lower urinary tract obstruction. - Glycyrrhitinic acid for overactive bladder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001912

Enrollment

Registered

2009-11-01

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder caused by lower urinary tract obstruction

Interventions

Therapeutic group

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 60-80 years old BPH patients maintained of alpha blocking agent with overactive bladder symptom. OABSS >5

Exclusion criteria

Exclusion criteria: (1) Central nervous system disease (2) Underactive bladder (3) Active UTI (4) active urothelial or prostatic cancer (5) maintained on anticholinergics (6) severe cardiac or renal dysfunction (7) maintained on diuretics (8) maintained on moxyfloxacin (9) serum K <3.5 (10) judged inelligible by physician

Design outcomes

Primary

Measure	Time frame
The improvement of IPSS and OABSS compared with pre-thrapeutic data	—

Countries

Japan

Contacts

Public ContactAkihrio Kanematsu

Kyoto University Urology

aqui@kuhp.kyoto-u.ac.jp075-751-3337

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026